Evaluation of efficacy of radioimmunotherapy with 90Y-labeled fully human anti-transferrin receptor monoclonal antibody in pancreatic cancer mouse models

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Sugyo, Aya ^a   Tsuji, Atsushi B ^a   Sudo, Hitomi ^a   Okada, Maki ^a   Koizumi, Mitsuru ^b   Satoh, Hirokazu ^c   Kurosawa, Gene ^d   Kurosawa, Yoshikazu ^d   Saga, Tsuneo ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

^c Perseus Proteomics   (Japan)

^d FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY Y 90; TRANSFERRIN RECEPTOR; TSP A01; TSP A01 DOTA; TSP A01 IN 111; TSP A01 Y 90; TSP A02; TSP A02 DOTA; TSP A02 IN 111; UNCLASSIFIED DRUG; CD31 ANTIGEN; INDIUM; YTTRIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG EFFICACY; DRUG RESPONSE; EXTERNAL BEAM RADIOTHERAPY; HUMAN; HUMAN CELL; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PROTEIN EXPRESSION; RADIATION DOSE; RADIOACTIVITY; RADIOIMMUNOTHERAPY; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; DISEASE MODEL; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METABOLISM; NUDE MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TUMOR CELL LINE;

MUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD31; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOHISTOCHEMISTRY; INDIUM RADIOISOTOPES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PANCREATIC NEOPLASMS; RADIOIMMUNOTHERAPY; RECEPTORS, TRANSFERRIN; TISSUE DISTRIBUTION; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 84929191518     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0123761     Document Type: Article

References (40)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64:9-29. doi: 10.3322/caac.21208 PMID: 24399786
2. Evans J, Chapple A, Salisbury H, Corrie P, Ziebland S. "It can't be very important because it comes and goes" - patients' accounts of intermittent symptoms preceding a pancreatic cancer diagnosis: a qualitative study. BMJ Open. 2014; 4: e004215. doi: 10.1136/bmjopen-2013-004215 PMID: 24549161
3. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010; 362: 1605-17. doi: 10.1056/NEJMra0901557 PMID: 20427809
4. Boyle P, Levin B. World cancer report 2008. Lyon: World Health Organization; 2008.
5. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014; 74: 2913-21. doi: 10.1158/0008-5472.CAN-14-0155 PMID: 24840647
6. Neckers LM, Trepel JB. Transferrin receptor expression and the control of cell growth. Cancer Invest. 1986; 4: 461-70. PMID: 3026588
7. Lesley JF, Schulte RJ. Inhibition of cell growth by monoclonal anti-transferrin receptor antibodies. Mol Cell Biol. 1985; 5: 1814-21. PMID: 3018527
8. Gatter KC, Brown G, Trowbridge IS, Woolston RE, Mason DY. Transferrin receptors in human tissues: Their distribution and possible clinical relevance. J Clin Pathol. 1983; 36: 539-45. PMID: 6302135
9. Panaccio M, Zalcberg JR, Thompson CH, Leyden MJ, Sullivan JR, Lichtenstein M, et al. Heterogeneity of the human transferrin receptor and use of anti-transferrin receptor antibodies to detect tumours in vivo. Immunol Cell Biol. 1987; 65 (Pt 6): 461-72. PMID: 2452131
10. Daniels TR, Delgado T, Rodríguez JA, Helguera G, Penichet ML. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol. 2006; 121: 144-58. PMID: 16904380
11. Ryschich E, Huszty G, Knaebel HP, Hartel M, Büchler MW, Schmidt J. Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas. Eur J Cancer. 2004; 40: 1418-22. PMID: 15177502
12. Daniels TR, Delgado T, Helguera G, Penichet ML. The transferrin receptor part II: Targeted delivery of therapeutic agents into cancer cells. Clin Immunol. 2006; 121: 159-76. PMID: 16920030
13. Daniels TR, Bernabeu E, Rodríguez JA, Patel S, Kozman M, Chiappetta DA, et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta. 2012; 1820: 291-317. doi: 10.1016/j.bbagen.2011.07.016 PMID: 21851850
14. 89Zr-labeled human antitransferrin receptor monoclonal antibody as a PET probe using a pancreatic cancer mouse model. Nucl Med Commun. 2015; 36: 286-94. doi: 10.1097/MNM.0000000000000245 PMID: 25460304
15. Cheson BD. Radioimmunotherapy of non-Hodgkin lymphomas. Blood. 2003; 101: 391-8. PMID: 12393555
16. Kassis AI. Therapeutic radionuclides: Biophysical and radiobiologic principles. Semin Nucl Med. 2008; 38: 358-66. doi: 10.1053/j.semnuclmed.2008.05.002 PMID: 18662557
17. Meares CF, Moi MK, Diril H, Kukis DL, McCall MJ, Deshpande SV, et al. Macrocyclic chelates of radiometals for diagnosis and therapy. Br J Cancer Suppl. 1990; 10: 21-6. PMID: 2383477
18. Sogawa C, Tsuji AB, Sudo H, Sugyo A, Yoshida C, Odaka K, et al. C-kit-targeted imaging of gastrointestinal stromal tumor using radiolabeled anti-c-kit monoclonal antibody in a mouse tumor model. Nucl Med Biol. 2010; 37: 179-87. doi: 10.1016/j.nucmedbio.2009.10.008 PMID: 20152717
19. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984; 72: 77-89. PMID: 6086763
20. Eckerman KF, Endo A. MIRD: Radionuclide data and decay schemes. Reston: The society of Nuclear Medicine and Molecular Imaging; 2008.
21. 90Y-labeled anti-c-kit antibodies in a mouse model of small cell lung cancer. PLoS ONE. 2013; 8: e59248. doi: 10.1371/journal.pone.0059248 PMID: 23516616
22. Sudo H, Tsuji AB, Sugyo A, Ogawa Y, Sagara M, Saga T. ZDHHC8 knockdown enhances radiosensitivity and suppresses tumor growth in a mesothelioma mouse model. Cancer Sci. 2012; 103: 203-9. doi: 10.1111/j.1349-7006.2011.02126.x PMID: 22017350
23. Trowbridge IS, Lopez F. Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits human tumor cell growth in vitro. Proc Natl Acad Sci U S A. 1982; 79: 1175-9. PMID: 6280171
24. Niitsu Y, Kohgo Y, Nishisato T, Kondo H, Kato J, Urushizaki Y, et al. Transferrin receptors in humancancerous tissues. Tohoku J Exp Med. 1987; 153: 239-43. PMID: 3433281
25. Halperin EC, Perez CA, Brady LW. Perez and Brady's principles and practice of radiation oncology. Philadelphia: Lippincott Williams & Wilkins; 2008.
26. Kano MR, Bae Y, Iwata C, Morishita Y, Yashiro M, Oka M, et al. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proc Natl Acad Sci U S A. 2007; 104: 3460-5. PMID: 17307870
27. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006; 6: 583-92. PMID: 16862189
28. Matsumura Y. Cancer stromal targeting (CAST) therapy. Adv Drug Deliv Rev. 2012; 64: 710-9. doi: 10.1016/j.addr.2011.12.010 PMID: 22212902
29. Buras RR, Wong JY, Kuhn JA, Beatty BG, Williams LE, Wanek PM, et al. Comparison of radioimmunotherapy and external beam radiotherapy in colon cancer xenografts. Int J Radiat Oncol Biol Phys. 1993; 25: 473-9. PMID: 8436526
30. Rucki AA, Zheng L. Pancreatic cancer stroma: understanding biology leads to new therapeutic strategies. World J Gastroenterol. 2014; 20: 2237-46. doi: 10.3748/wjg.v20.i9.2237 PMID: 24605023
31. Vogel CA, Galmiche MC, Buchegger F. Radioimmunotherapy and fractionated radiotherapy of human colon cancer liver metastases in nude mice. Cancer Res. 1997; 57: 447-53. PMID: 9012472
32. 131I radioimmunotherapy and fractionated external beam radiotherapy: comparative effectiveness in a human tumor xenograft. J Nucl Med. 1999; 40: 1764-8. PMID: 10520720
33. Koppe MJ, Oyen WJG, Bleichrodt RP, Verhofstad AA, Goldenberg DM, Boerman OC. Combination therapy using gemcitabine and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin. Cancer Biother Radiopharm. 2006; 21: 506-14. PMID: 17105422
34. van Bree C, Rodermond HM, Leen R, Medema JP, van Kuilenburg ABP. Cyclopentenyl cytosine increases gemcitabine radiosensitisation in human pancreatic cancer cells. Br J Cancer. 2008; 98: 1226-33. doi: 10.1038/sj.bjc.6604287 PMID: 18349845
35. Donohue E, Thomas A, Maurer N, Manisali I, Zeisser-Labouebe M, Zisman N, et al. The autophagy inhibitor verteporfin moderately enhances the antitumor activity of gemcitabine in a pancreatic ductal adenocarcinoma model. J Cancer. 2013; 4: 585-96. doi: 10.7150/jca.7030 PMID: 24069069
36. Knoop RF, Sparn M, Waldmann J, Plassmeier L, Bartsch DK, Lauth M, et al. Chronic pancreatitis and systemic inflammatory response syndrome prevent impact of chemotherapy with gemcitabine in a genetically engineered mouse model of pancreatic cancer. Neoplasia. 2014; 16: 463-70. doi: 10.1016/j.neo.2014.05.010 PMID: 24953430
37. Graf F, Fahrer J, Maus S, Morgenstern A, Bruchertseifer F, Venkatachalam S, et al. DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy. PLoS ONE. 2014; 9: e88239. doi: 10.1371/journal.pone.0088239 PMID: 24516620
38. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009; 324: 1457-61. doi: 10.1126/science.1171362 PMID: 19460966
39. 90Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria. J Clin Oncol. 2014; 32: 212-8. doi: 10.1200/JCO.2013.50.3110 PMID: 24297953
40. Klee GG. Human anti-mouse antibodies. Arch Pathol Lab Med. 2000; 124: 921-3. PMID: 10835540